110 related articles for article (PubMed ID: 7612258)
1. The prognostic significance of immunohistochemically detectable metallothionein in primary breast carcinomas.
Haerslev T; Jacobsen GK; Zedeler K
APMIS; 1995 Apr; 103(4):279-85. PubMed ID: 7612258
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of metallothionein in primary breast carcinomas and their axillary lymph node metastases.
Haerslev T; Jacobsen K; Nedergaard L; Zedeler K
Pathol Res Pract; 1994 Aug; 190(7):675-81. PubMed ID: 7808966
[TBL] [Abstract][Full Text] [Related]
3. Localization of metallothionein in breast carcinomas. An immunohistochemical study.
Fresno M; Wu W; Rodriguez JM; Nadji M
Virchows Arch A Pathol Anat Histopathol; 1993; 423(3):215-9. PubMed ID: 8236816
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
5. Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast.
Schmid KW; Ellis IO; Gee JM; Darke BM; Lees WE; Kay J; Cryer A; Stark JM; Hittmair A; Ofner D
Virchows Arch A Pathol Anat Histopathol; 1993; 422(2):153-9. PubMed ID: 8385380
[TBL] [Abstract][Full Text] [Related]
6. Proliferating cell nuclear antigen in breast carcinomas. An immunohistochemical study with correlation to histopathological features and prognostic factors.
Haerslev T; Jacobsen GK
Virchows Arch; 1994; 424(1):39-46. PubMed ID: 7981902
[TBL] [Abstract][Full Text] [Related]
7. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis.
Zhang R; Zhang H; Wei H; Luo X
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):95-7. PubMed ID: 10905514
[TBL] [Abstract][Full Text] [Related]
8. Metallothionein expression in invasive and in situ breast carcinomas.
Gallicchio LM; Flaws JA; Fowler BA; Ioffe OB
Cancer Detect Prev; 2005; 29(4):332-7. PubMed ID: 16122884
[TBL] [Abstract][Full Text] [Related]
9. Mean nuclear area and metallothionein expression in ductal breast tumors: correlation with estrogen receptor status.
El Sharkawy SL; Farrag AR
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):108-12. PubMed ID: 18227734
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions.
Bier B; Douglas-Jones A; Tötsch M; Dockhorn-Dworniczak B; Böcker W; Jasani B; Schmid KW
Breast Cancer Res Treat; 1994; 30(3):213-21. PubMed ID: 7981441
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis.
Oyama T; Take H; Hikino T; Iino Y; Nakajima T
Oncology; 1996; 53(2):112-7. PubMed ID: 8604236
[TBL] [Abstract][Full Text] [Related]
12. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas.
Haerslev T; Jacobsen GK; Zedeler K
Breast Cancer Res Treat; 1996; 37(2):101-13. PubMed ID: 8750578
[TBL] [Abstract][Full Text] [Related]
13. Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance.
Surowiak P; Matkowski R; Materna V; Györffy B; Wojnar A; Pudelko M; Dziegiel P; Kornafel J; Zabel M
Histol Histopathol; 2005 Oct; 20(4):1037-44. PubMed ID: 16136485
[TBL] [Abstract][Full Text] [Related]
14. [Proliferation index and its prognostic value in invasive ductal breast carcinoma].
Falco M
Ann Acad Med Stetin; 2009; 55(1):22-30. PubMed ID: 20349588
[TBL] [Abstract][Full Text] [Related]
15. Immunoreactive p53 and metallothionein expression in duct carcinoma in situ of the breast. No correlation.
Douglas-Jones AG; Navabi H; Morgan JM; Jasani B
Virchows Arch; 1997 May; 430(5):373-9. PubMed ID: 9174627
[TBL] [Abstract][Full Text] [Related]
16. Correlation between metallothionein (MT) expression and selected prognostic factors in ductal breast cancers.
Gomulkiewicz A; Podhorska-Okolow M; Szulc R; Smorag Z; Wojnar A; Zabel M; Dziegiel P
Folia Histochem Cytobiol; 2010 Jan; 48(2):242-8. PubMed ID: 20675281
[TBL] [Abstract][Full Text] [Related]
17. Metallothionein-overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients.
Weinlich G; Bitterlich W; Mayr V; Fritsch PO; Zelger B
Br J Dermatol; 2003 Sep; 149(3):535-41. PubMed ID: 14510986
[TBL] [Abstract][Full Text] [Related]
18. Proliferating cell nuclear antigen (pcna) and C-erbb-2 oncoprotein in breast-carcinoma with correlations to histopathological parameters and prognosis.
Haerslev T; Jacobsen G; Zedeler K
Oncol Rep; 1995 Jan; 2(1):99-105. PubMed ID: 21597698
[TBL] [Abstract][Full Text] [Related]
19. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study.
Yoshioka T; Umekita Y; Ohi Y; Souda M; Sagara Y; Sagara Y; Sagara Y; Rai Y; Tanimoto A
Histopathology; 2011 Mar; 58(4):608-16. PubMed ID: 21371077
[TBL] [Abstract][Full Text] [Related]
20. [Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases--immunohistochemical investigations of routine formalin-fixed paraffin-embedded tissue].
Schulze MH; Buchmann J
Zentralbl Gynakol; 2000; 122(2):92-5. PubMed ID: 10721188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
